Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-130A versus Xalatan in open-angle glaucoma or ocular hypertension
2017-004262-95Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Catiolanze, latanoprost in open-angle glaucoma (OAG), ocular hypertension, sponsored by Santen Pharmaceutical. Started Nov 2018; status: completed.
02
Drugs
Catiolanzelatanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2017-004262-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004262-95.